This case study on Lantus is the second of a series of in-depth investigations into the best-selling medicines in I-MAK’s Overpatented, Overpriced report.
Key findings
Overpatented, Overpriced: Lantus
95% of the patent applications on the diabetes drug Lantus
(insulin glargine) were filed after the drug was on the market.
Read our 2018 report to find out more.
Learn more about how you can help build a more equitable system for all